John N. Staffurth
Cardiff, WLS, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT.
Journal: Clinical and translational radiation oncology
Published: February 04, 2026
Hippocampal Dosimetry and Implication for Treatment Planning in Patients Undergoing Stereotactic Radiosurgery for Limited Brain Metastases.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: July 21, 2025
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.
Journal: Nature cancer
Published: July 18, 2025
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial.
Journal: European urology oncology
Published: March 03, 2025
Real-World Experience of 18F-PSMA-1007 Positron Emission Tomography-Computed Tomography Scanning for Initial Staging of High-Risk Nonmetastatic Prostate Cancer: Scan Results and Treatment Decisions.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: January 30, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.
Journal: The Lancet. Oncology
Published: December 20, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
Journal: The New England journal of medicine
Published: October 16, 2024
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
Journal: NEJM evidence
Published: February 06, 2024
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Journal: Cells
Published: December 22, 2023
The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study.
Journal: PloS one
Published: August 12, 2023
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Journal: JNCI cancer spectrum
Published: April 13, 2023
Last Updated: 09/26/2026